Comparison of clinical efficacy of topical pimecrolimus with betamethasone in chronic skin lesions due to sulfur mustard exposure: A randomized, investigator-blind study

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 2, 2009, Pages 171-175

  Panahi, Yunes ^a   Moharamzad, Yashar ^a   Beiraghdar, Fatemeh ^a   Naghizadeh, Mohammad Mehdi ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; MUSTARD GAS; PIMECROLIMUS;

APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; ARTICLE; CHEMICAL INJURY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRY SKIN; HUMAN; INGUINAL REGION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN BURNING SENSATION; SKIN INJURY; SKIN PRURITUS; VISUAL ANALOG SCALE; WAR;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CHEMICAL WARFARE AGENTS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; MUSTARD GAS; OINTMENTS; PRURITUS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TACROLIMUS; TREATMENT OUTCOME;

EID: 58449091585     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00356.x     Document Type: Article

References (28)

1. Wormser U. Toxicology of mustard gas. Trends Pharmacol Sci 1991 12 : 164 67.
2. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006 99 : 273 82.
3. Balali-Mood M, Hefazi M, Mahmoudi M, Jalali E, Attaran D, Maleki M et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol 2005 19 : 713 21.
4. United Nations Security Council. Reports of the specialists appointed by the Secretary General to investigate allegations by the Islamic Republic of Iran concerning the use of chemical weapons. New York : Security Council of the United Nations document S/16433, 1986.
5. Balali-Mood M, Hefazi M. The clinical toxicology of sulfur mustard. Arch Iranian Med 2005 8 : 162 79.
6. Hefazi M, Maleki M, Mahmoudi M, Tabatabaee A, Balai-Mood M. Delayed complications of sulfur mustard poisoning in the skin and the immune system of Iranian veterans 16-20 years after exposure. Int J Dermatol 2006 45 : 1025 31.
7. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003 45 : 1136 43.
8. Momeni AZ, Enshaeih S, Meghdadi M, Amindjavaheri M. Skin manifestations of mustard gas. A clinical study of 535 patients exposed to mustard gas. Arch Dermatol 1992 128 : 775 80.
9. Shohrati M, Peyman M, Peyman A, Davoudi M, Ghanei M. Cutaneous and ocular late complications of sulfur mustard in Iranian veterans. Cutan Ocul Toxicol 2007 26 : 73 81.
10. Rice P. Sulfur mustard injuries of the skin. Pathophysiology and management. Toxicol Rev 2003 22 : 111 8.
11. Henqque UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006 54 : 1 15.
12. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006 15 : 406 20.
13. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005 330 : 516.
14. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003 111 : 1153 68.
15. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004 208 : 365 72.
16. Wollina U. The role of topical calcineurin inhibitors for skin disease other than atopic dermatitis. Am J Clin Dermatol 2007 8 : 157 73.
17. Long CC, Finlay AY. The finger-tip unit: a new practical measure. Clin Exp Dermatol 1991 16 : 444 7.
18. Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 1998 78 : 395 402.
19. Smith T. Ethics in Medical Research, 1st edn. Cambridge University Press, Cambridge, UK, 1999.
20. Arroyo CM, Schafer RJ, Kurt EM, Broomfield CA, Carmichael AJ. Response of normal human keratinocytes to sulfur mustard (HD): cytokine release using a non-enzymatic detachment procedure. Hum Exp Toxicol 1999 18 : 1 11.
21. Arroyo CM, Schafer RJ, Kurt EM, Broomfield CA, Carmichael AJ. Response of normal human keratinocytes to sulfur mustard: cytokine release. J Appl Toxicol. 2000 20 (Suppl. 1 S63 72.
22. Smith WJ, Dunn MA. Medical defense against blistering chemical warfare agents. Arch Dermatol 1991 127 : 1207 13.
23. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002 62 : 817 40.
24. Panahi Y, Davoudi SM, Sadr SB, Naghizadeh MM, Mohammadi-Mofrad M. Impact of pruritus on quality of life in sulfur mustard-exposed Iranian veterans. Int J Dermatol 2008 47 : 557 61.
25. Shohrati M, Tajik A, Harandi AA, Davoudi SM, Akmasi M. Comparison of hydroxyzine and doxepin in treatment of pruritus due to sulfur mustard. Skinmed 2007 6 : 70 72.
26. Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A. Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol 2007 26 : 249 55.
27. Panahi Y, Davoodi SM, Khalili H, Dashti-Khavidaki S, Bigdeli M. Phenol and menthol in the treatment of chronic skin lesions following mustard gas exposure. Singapore Med J 2007 48 : 392 95.
28. Luger TA, Gollnick H, Schwennesen T, Bextermoller R, Freytaq S, Brautigam M. Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis. J Dtsch Dermatol Ges 2007 5 : 908 14.